Ignite Creation Date:
2024-05-05 @ 11:22 AM
Last Modification Date:
2024-10-26 @ 9:01 AM
Study NCT ID:
NCT00000297
Status:
COMPLETED
Last Update Posted:
2017-01-12
First Post:
1999-09-20
Brief Title:
Effects of Labetalol on Nicotine Administration in Humans - 14
Sponsor:
National Institute on Drug Abuse NIDA
Organization:
National Institute on Drug Abuse NIDA
Study Overview
Official Title:
Effects of Labetalol on Nicotine Administration in Humans
Status:
COMPLETED
Status Verified Date:
1998-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to investigate the effects of labetalol in response to intravenous nicotine
Detailed Description:
The purpose of this study is to determine whether labetalol an alpha and beta adrenergic blocker will block the subjective and physiological effects of intravenously administered nicotine in humans A total of 12 subjects will participate in the double blind placebo controlled outpatient study Subjects will have 3 separate experimental sessions 3-9 days apart On each of the experimental sessions a single oral dose of low 100mg or high dose of labetalol 200mg or placebo will be administered Two hours after labetalol or placebo treatment subjects will receive 15 variance grams nicotine basekg intravenously Several physiological endocrine and subjective measures will be obtained during the sessions We propose that blockage of adrenergic receptors by labetalol will significantly block the physological and subjective effects of nicotine
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| P50-09259-14 | None | None | None |